Department of Neonatology, Kovai Medical Center and Hospital (KMCH) & KMCH Institute of Health Sciences and Research, Coimbatore, India.
Ankura Hospital for Women and Children, Hyderabad, India.
JAMA Pediatr. 2022 May 1;176(5):502-516. doi: 10.1001/jamapediatrics.2021.6619.
Bronchopulmonary dysplasia (BPD) has multifactorial etiology and long-term adverse consequences. An umbrella review enables the evaluation of multiple proposed interventions for the prevention of BPD.
To summarize and assess the certainty of evidence of interventions proposed to decrease the risk of BPD from published systematic reviews.
MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, and Web of Science were searched from inception until November 9, 2020.
Meta-analyses of randomized clinical trials comparing interventions in preterm neonates that included BPD as an outcome.
Data extraction was performed in duplicate. Quality of systematic reviews was evaluated using Assessment of Multiple Systematic Reviews version 2, and certainty of evidence was assessed using Grading of Recommendation, Assessment, Development, and Evaluation.
(1) BPD or mortality at 36 weeks' postmenstrual age (PMA) and (2) BPD at 36 weeks' PMA.
A total of 154 systematic reviews evaluating 251 comparisons were included, of which 110 (71.4%) were high-quality systematic reviews. High certainty of evidence from high-quality systematic reviews indicated that delivery room continuous positive airway pressure compared with intubation with or without routine surfactant (relative risk [RR], 0.80 [95% CI, 0.68-0.94]), early selective surfactant compared with delayed selective surfactant (RR, 0.83 [95% CI, 0.75-0.91]), early inhaled corticosteroids (RR, 0.86 [95% CI, 0.75-0.99]), early systemic hydrocortisone (RR, 0.90 [95% CI, 0.82-0.99]), avoiding endotracheal tube placement with delivery room continuous positive airway pressure and use of less invasive surfactant administration (RR, 0.90 [95% CI, 0.82-0.99]), and volume-targeted compared with pressure-limited ventilation (RR, 0.73 [95% CI, 0.59-0.89]) were associated with decreased risk of BPD or mortality at 36 weeks' PMA. Moderate to high certainty of evidence showed that inhaled nitric oxide, lower saturation targets (85%-89%), and vitamin A supplementation are associated with decreased risk of BPD at 36 weeks' PMA but not the competing outcome of BPD or mortality, indicating they may be associated with increased mortality.
A multipronged approach of delivery room continuous positive airway pressure, early selective surfactant administration with less invasive surfactant administration, early hydrocortisone prophylaxis in high-risk neonates, inhaled corticosteroids, and volume-targeted ventilation for preterm neonates requiring invasive ventilation may decrease the combined risk of BPD or mortality at 36 weeks' PMA.
支气管肺发育不良(BPD)病因复杂,具有长期不良后果。伞式审查可评估多种预防 BPD 的干预措施。
总结和评估已发表的系统评价中提出的降低 BPD 风险的干预措施的证据确定性。
从建库到 2020 年 11 月 9 日,在 MEDLINE、Cochrane 对照试验中心注册库、EMBASE 和 Web of Science 中进行了搜索。
比较早产儿干预措施的随机临床试验的荟萃分析,这些干预措施将 BPD 作为结局。
数据提取由两人独立进行。使用评估多个系统评价 2 版评估系统评价的质量,使用推荐评估、制定与评估分级评估证据确定性。
(1)36 周校正胎龄(PMA)时的 BPD 或死亡率,以及(2)36 周 PMA 时的 BPD。
共纳入 154 项系统评价,评估了 251 项比较,其中 110 项(71.4%)为高质量系统评价。高质量系统评价的高确定性证据表明,与气管插管加或不加常规表面活性剂相比,产房持续气道正压通气(RR,0.80[95%CI,0.68-0.94])、早期选择性表面活性剂与延迟选择性表面活性剂(RR,0.83[95%CI,0.75-0.91])、早期吸入皮质激素(RR,0.86[95%CI,0.75-0.99])、早期全身皮质醇(RR,0.90[95%CI,0.82-0.99])、避免气管插管与产房持续气道正压通气并用和使用较少侵入性表面活性剂给药(RR,0.90[95%CI,0.82-0.99])、以及容量目标通气与压力限制通气(RR,0.73[95%CI,0.59-0.89])与 36 周 PMA 时的 BPD 或死亡率降低有关。中等至高度确定性证据表明,吸入性一氧化氮、饱和度目标较低(85%-89%)和维生素 A 补充与 36 周 PMA 时的 BPD 风险降低有关,但与 BPD 或死亡率的竞争结局无关,这表明它们可能与死亡率升高有关。
产房持续气道正压通气、早期选择性表面活性剂与较少侵入性表面活性剂给药联合应用、高危新生儿早期皮质醇预防、吸入皮质激素和需要有创通气的早产儿容量目标通气的多管齐下的方法可能降低 36 周 PMA 时 BPD 或死亡率的综合风险。